Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol PTPI
- Company Petros Pharmaceuticals, Inc.
- Price $0.42
- Changes Percentage 30.44
- Change 0.0974
- Day Low $0.32
- Day High $0.44
- Year High $2.27
- Year Low $0.28
- Market Cap $4,075,352
- Price Avg 50 EMA (D) $0.34
- Price Avg 200 EMA (D) $0.76
- Exchange NASDAQ
- Volume 1,769,818
- Average Volume 164,242
- Open $0.33
- Previous Close $0.32
- EPS -6.25
- PE -0.07
- Earnings Announcement 2024-11-27 12:00:00
- Shares Outstanding $9,763,660
Company brief: PETROS PHARMACEUTICALS, INC. (PTPI )
- Healthcare
- Drug Manufacturers - Specialty & Generic
- Mr. John David Shulman
- https://www.petrospharma.com
- US
- N/A
- 12-02-2020
- US71678J2096
Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a patented topical formulation candidate for the treatment of acute Peyronie's disease. The company markets its line of ED products in the form of vacuum erection device products. Petros Pharmaceuticals, Inc. is based in New York, New York.